Artwork

AWS Startups에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 AWS Startups 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

#85, Unlocking the Secrets of Cells with AI, Jonathan Baptista from DeepLife

30:48
 
공유
 

Manage episode 415395100 series 3291628
AWS Startups에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 AWS Startups 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

Exploring the intersection of AI and biology, this episode features Jonathan Baptista, Co-Founder and CEO of DeepLife. DeepLife uses machine learning to curate and annotate single-cell RNA-seq datasets, enabling downstream bioinformatics analysis and target identification. Host Alex Merwin from AWS learns all about DeepLife's groundbreaking approach to accelerating drug discovery and precision medicine through AI-driven simulations and generative models.

  1. How does DeepLife leverage AI for drug discovery simulations?
    • DeepLife creates digital twins of cells, enabling virtual experimentation and mechanistic modeling to identify potential drug targets without extensive lab testing. Their platform simulates cellular responses to perturbations, providing insights into disease mechanisms and therapeutic opportunities.
  2. What inspired Jonathan Baptista's pivot from aerospace to computational biology?
    • Jonathan's background in aerospace engineering inspired applying simulation tools to complex biological systems, inferring "laws" from data using AI/ML techniques instead of defined physics equations. This approach aims to accelerate drug discovery for precision medicine.
  3. How does DeepLife map the biomolecular landscape?
    • DeepLife spent years developing pipelines to harmonize and annotate high-quality biomolecular data from public repositories and partners, mapping available datasets to identify therapeutic areas suitable for their AI-driven modeling approach.
  4. How does DeepLife leverage generative AI for biomedicine?
    • Leveraging recent advances in generative AI models for text and images, DeepLife improved annotation and simulation of cell states after perturbations, benchmarking and selecting optimal techniques for different drug discovery tasks.
  5. What is DeepLife's "collaborative AI" approach?
    • DeepLife's "collaborative AI" approach generates potential biological hypotheses that researchers can validate and explore further, enabling visualization of simulated cells and predicted perturbations to uncover novel mechanistic insights.

Learn more about DeepLife here and their mission to build the next generation of system biology.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

  continue reading

116 에피소드

Artwork
icon공유
 
Manage episode 415395100 series 3291628
AWS Startups에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 AWS Startups 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

Exploring the intersection of AI and biology, this episode features Jonathan Baptista, Co-Founder and CEO of DeepLife. DeepLife uses machine learning to curate and annotate single-cell RNA-seq datasets, enabling downstream bioinformatics analysis and target identification. Host Alex Merwin from AWS learns all about DeepLife's groundbreaking approach to accelerating drug discovery and precision medicine through AI-driven simulations and generative models.

  1. How does DeepLife leverage AI for drug discovery simulations?
    • DeepLife creates digital twins of cells, enabling virtual experimentation and mechanistic modeling to identify potential drug targets without extensive lab testing. Their platform simulates cellular responses to perturbations, providing insights into disease mechanisms and therapeutic opportunities.
  2. What inspired Jonathan Baptista's pivot from aerospace to computational biology?
    • Jonathan's background in aerospace engineering inspired applying simulation tools to complex biological systems, inferring "laws" from data using AI/ML techniques instead of defined physics equations. This approach aims to accelerate drug discovery for precision medicine.
  3. How does DeepLife map the biomolecular landscape?
    • DeepLife spent years developing pipelines to harmonize and annotate high-quality biomolecular data from public repositories and partners, mapping available datasets to identify therapeutic areas suitable for their AI-driven modeling approach.
  4. How does DeepLife leverage generative AI for biomedicine?
    • Leveraging recent advances in generative AI models for text and images, DeepLife improved annotation and simulation of cell states after perturbations, benchmarking and selecting optimal techniques for different drug discovery tasks.
  5. What is DeepLife's "collaborative AI" approach?
    • DeepLife's "collaborative AI" approach generates potential biological hypotheses that researchers can validate and explore further, enabling visualization of simulated cells and predicted perturbations to uncover novel mechanistic insights.

Learn more about DeepLife here and their mission to build the next generation of system biology.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

  continue reading

116 에피소드

Alla avsnitt

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드